| 000 | 01392 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517174835.0 | ||
| 264 | 0 | _c20180621 | |
| 008 | 201806s 0 0 eng d | ||
| 022 | _a1875-9114 | ||
| 024 | 7 |
_a10.1002/phar.2035 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAli, Ayad K | |
| 245 | 0 | 0 |
_aPharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. _h[electronic resource] |
| 260 |
_bPharmacotherapy _cNov 2017 |
||
| 300 |
_a1383-1390 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aBayes Theorem |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
| 650 | 0 | 4 |
_aIpilimumab _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aNivolumab |
| 650 | 0 | 4 | _aPharmacovigilance |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aWatson, David E | |
| 773 | 0 |
_tPharmacotherapy _gvol. 37 _gno. 11 _gp. 1383-1390 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/phar.2035 _zAvailable from publisher's website |
| 999 |
_c27604147 _d27604147 |
||